Serum miR-148a, miR-148b, and miR-152 were significantly downregulated in NSCLC patients. The combination of four candidate miRNAs exhibited the highest predictive accuracy in non-small cell lung cancer screening compared

our data indicate that decreased expression of miR-148b in non-small cell lung cancer tissues has prognostic value.

relative expression levels of miR-148/152 family (miR-148a, miR-148b, and miR-152) in serum of 36 non-small-cell lung carcinoma patients, 20 patients with benign pulmonary diseases, and 10 healthy individuals

miR-148b mimic sensitized A549 xenografts to irradiation in vivo Our study demonstrated that miR-148b regulates radioresistance of lung cancer cells by modulating MLH1 expression level. miR-148b may represent a new therapeutic target for the intervention of lung cancer.

Data suggest that lower expression of microRNA-148b in lung of patients with non-small cell lung cancer (NSCLC) is positively associated with advanced tumor stage and radioresistance and predicts poor survival in patients with or without radiotherapy; thus, microRNA-148b may be an independent prognostic biomarker for NSCLC.

MiR-148b-3p was significantly associated with tumor grade and tumor size in lung adenocarcinoma, and served as an independent predictor of overall survival of patients with lung adenocarcinoma

Long non-coding RNA H19 confers resistance to gefitinib via miR-148b-3p/DDAH1 axis in lung adenocarcinoma.

MiR-148b suppressed non-small cell lung cancer progression via inhibiting ALCAM through the NF-kappaB signaling pathway.